Lanreotide Injection Syringe Needle Diameter Viscosity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current lanreotide compositions for sustained release are challenging to administer due to their high viscosity, requiring large needles that cause pain and form nodules, limiting injection routes and precision.

Innovation Solution

Development of new injectable compositions with lanreotide concentrations between 11% to 25% in an aqueous solvent, optionally with amino acids like arginine, packaged in syringes with diameters greater than 3.00 mm and equipped with thinner needles, allowing for more precise and comfortable injections.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If high viscosity lanreotide compositions are used for sustained release, then controlled release profile is achieved, but injection force increases and needle diameter must be increased

Engineering Contradiction:

Improvesustained release periodVSAvoidinjection force

Core Design Contradiction:

Duration of action of moving objectVSForce

Solution Approach 1:

The patent changes the concentration parameter of lanreotide from high (25% or more) to moderate (11-25%), which fundamentally alters the viscosity characteristics of the composition. This parameter change enables the composition to be injected through thinner needles while still achieving sustained release效果, thus resolving the contradiction between sustained release duration and injection force

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces amino acids (particularly arginine) as intermediary substances that modify the physical properties of the lanreotide composition. These intermediaries help reduce viscosity and facilitate injection through thinner needles while maintaining the sustained release capability, effectively mediating between the conflicting requirements of controlled release and ease of injection

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If large diameter needles are used to administer high viscosity compositions, then injection is feasible, but pain increases and nodule formation occurs

Engineering Contradiction:

Improveinjection feasibilityVSAvoidpain and nodule formation

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

By changing the concentration parameter of lanreotide to 11-25%, the composition's viscosity is reduced to a level that can be injected through thinner needles. This parameter change directly addresses the contradiction by enabling the use of smaller needles (reducing pain and nodule formation) while still maintaining injection feasibility

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent optimizes the local quality of the composition by adjusting lanreotide concentration and adding amino acids, creating a composition with appropriate viscosity characteristics for specific injection routes. This allows different injection sites (intramuscular, intradermal, subcutaneous) to be used with appropriate needle sizes, reducing local harmful effects while maintaining ease of operation

Inventive Principle:

Principle #3Local quality

3Duration of action of moving object

If high concentration lanreotide compositions are used, then sustained release is achieved, but injection routes are limited

Engineering Contradiction:

Improverelease periodVSAvoidinjection route flexibility

Core Design Contradiction:

Duration of action of moving objectVSAdaptability or versatility

Solution Approach 1:

The patent changes the concentration parameter to a moderate range (11-25%) and adjusts the composition's physical properties by adding amino acids. This parameter optimization enables the composition to be adapted to multiple injection routes (intramuscular, intradermal, subcutaneous) while maintaining sustained release characteristics, thus resolving the contradiction between release duration and route versatility

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The optimized composition with lanreotide at 11-25% concentration and added amino acids achieves multi-functionality by being suitable for multiple injection routes. This universal composition can be administered intramuscularly, intradermally, or subcutaneously, all while maintaining controlled sustained release, thereby eliminating the limitation of injection route flexibility

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS12201674B2Injectable presentations, syringes and compositions with sustained and/or controlled release of lanreotide

Publication Date: 2025.01.21 EDIX SA

AI summary

The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.